Prof. Denis Poddubny (Charité-Universitätsmedizin Berlin, Berlin, Germany) kindly took the time to speak with touchIMMUNOLOGY about the post-hoc analysis from the phase 3b SKIPPAIN trial (NCT03136861) aimed at exploring the potential association of HLA-B27 subtypes on the effect of secukinumab in patients with axSpA.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
His presentation entitled ‘Efficacy of Secukinumab and HLA-B27 Subtypes: Results from a Phase IIIb Randomised Controlled Trial in Axial SpA’ (ABSTRACT NUMBER: 0917) was presented at the ACR Convergence, 5-9 November 2021.
Questions
- What is known about the association between human leukocyte antigen (HLA) subtypes and axial spondyloarthritis? (0:12)
- What were the aims and methodology of this post hoc analysis of the SKIPPAIN trial data? (1:15)
- What were the findings of the analysis? (1:40)
- What questions remain unanswered about HLA-B27 subtypes and what future studies are planned? (2:17)
Disclosures: Prof. Denis Poddubnyy has received research support from AbbVie, Eli Lilly, MSD, Novartis, and Pfizer; consulting fees from AbbVie, Biocad, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, Samsung Bioepis, and UCB; and speaker fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
